EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant

Emerson M Wickwire, Jingsong Zhou, Shuo Chen, Kristine A Wilckens, Timothy A Steenbergh, Daniel J Buysse, Avelino C Verceles

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2025.50186 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Emerson M Wickwire und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Triazoles, Azepines, Smartphone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Daytime symptoms, including negative mood, fatigue, and cognitive impairment, are core features and diagnostic criteria for insomnia disorder. Historically, assessment of these daytime insomnia symptoms has relied on retrospective questionnaires with varying recall periods and that may lack sensitivity to detect subtle change attributable to insomnia treatment.

Objective

To use smartphone-based ecological momentary assessment (EMA) to determine the effect of insomnia pharmacotherapy on daytime insomnia symptoms. Design, Setting, and Participants This was a double-blind, placebo-controlled randomized clinical trial. All procedures were conducted remotely between October 9, 2023, and August 8, 2024. Following baseline assessment, participants were randomized to suvorexant or placebo, including 2 nights at 10 mg then 14 nights at 20 mg. Participants completed the Daytime Insomnia Symptoms Scale (DISS) 4 times per day (ie, 64 administrations over 16 days) and a posttreatment assessment. Participants were recruited from an academic center. Inclusion criteria were individuals aged 60 to 85 years, diagnosed with chronic insomnia per clinical interview, with moderate to severe insomnia symptoms (Insomnia Severity Index [ISI] ≥15), and owning a smartphone. Exclusion criteria were major untreated medical or psychiatric condition, contraindications for a dual-orexin receptor antagonist, refusal to discontinue other insomnia medications, or severe obstructive sleep apnea. Data were analyzed between September 6, 2024, and October 28, 2025.

Intervention

Suvorexant 20 mg nightly vs placebo. Main Outcomes and Measures The primary EMA measure was the DISS. During baseline and posttreatment assessments, participants also completed questionnaires assessing insomnia severity, sleepiness, fatigue, anxiety, and depression.

Results

Participants included 40 older adults (mean [SD] age, 67.9 [5.4] years; 36 [90%] women), with 20 participants randomized to suvorexant and 20 to placebo. There were no dropouts. The overall completion rate for EMA surveys was 93.3%. Relative to placebo, suvorexant reduced insomnia severity (mean [SD] change in ISI, −9.6 [5.4] vs −5.5 [6.8]; estimate [SE], 4.1 [1.9]; t = 2.1; df = 36; P = .04, effect size, 0.66 [95% CI, 0.02 to 1.30]). Based on retrospective questionnaires, no statistically significant between-group differences in daytime insomnia symptoms were detected. Based on EMA, significant between-group differences were detected in subjective cognition (χ 2 4 = 11.12; P = .03) and fatigue (χ 2 4 = 21.43; P = .003) at 1 or more times of day. Conclusions and Relevance In this randomized clinical trial of older adults with insomnia, although traditional outcomes assessments detected no between-group differences, EMA was sensitive to detect effects of insomnia pharmacotherapy on daytime insomnia symptoms at various times of day, a critical gap in the literature. Trial Registration ClinicalTrials.gov Identifier: NCT05908526

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersTriazolesAzepinesSmartphoneSleep Aids, PharmaceuticalEcological Momentary AssessmentOrexin Receptor AntagonistsHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedAged, 80 and over

Substanzen

suvorexantTriazolesAzepinesSleep Aids, PharmaceuticalOrexin Receptor Antagonists

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
  • Departments of Biostatistics, University of Maryland School of Medicine, Baltimore.
  • Department of Statistics, University of Maryland, College Park.
  • Department of Psychology, Indiana Wesleyan University, Marion, Indiana.
  • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Zitieren

APA

Wickwire, E. M., Zhou, J., Chen, S., Wilckens, K. A., Steenbergh, T. A., Buysse, D. J., & Verceles, A. C. (2026). Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.50186

Vancouver

Wickwire EM, Zhou J, Chen S, Wilckens KA, Steenbergh TA, Buysse DJ, et al. Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.50186

BibTeX
@article{Wickwire2026,
  author = {Wickwire, Emerson M and Zhou, Jingsong and Chen, Shuo and Wilckens, Kristine A and Steenbergh, Timothy A and Buysse, Daniel J and Verceles, Avelino C},
  title = {Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2025.50186}
}
Kostenlos starten →